SMO and chronic myelogenous leukemia, BCR-ABL1 positive: Experiments using murine models of CML have demonstrated that Smo deletion or pharmacological inhibition results in reduced LSC and a greatly reduced capacity to recrudesce the disease in secondary hosts24, 27.